Risk-based prostate cancer screening

Who and how?

Allison S. Glass, K. Clinton Cary, Matthew R. Cooperberg

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The purpose of this review is to identify clinical risk factors for prostate cancer and to assess the utility and limitations of our current tools for prostate cancer screening. Prostate-specific antigen is the single most important factor for identifying men at increased risk of prostate cancer but is best assessed in the context of other clinical factors; increasing age, race, and family history are well-established risk factors for the diagnosis of prostate cancer. In addition to clinical risk calculators, novel tools such as multiparametric imaging, serum or urinary biomarkers, and genetic profiling show promise in improving prostate cancer diagnosis and characterization. Optimal use of existing and future tools will help alleviate the problems of overdiagnosis and overtreatment of low-risk prostate cancer without reversing the substantial mortality declines that have been achieved in the screening era.

Original languageEnglish (US)
Pages (from-to)192-198
Number of pages7
JournalCurrent Urology Reports
Volume14
Issue number3
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Prostate-Specific Antigen
Biomarkers
Mortality
Serum

Keywords

  • Clinical risk
  • Prostate cancer
  • Prostate-specific antigen
  • Risk-based
  • Screening tools

ASJC Scopus subject areas

  • Urology

Cite this

Risk-based prostate cancer screening : Who and how? / Glass, Allison S.; Cary, K. Clinton; Cooperberg, Matthew R.

In: Current Urology Reports, Vol. 14, No. 3, 06.2013, p. 192-198.

Research output: Contribution to journalArticle

Glass, Allison S. ; Cary, K. Clinton ; Cooperberg, Matthew R. / Risk-based prostate cancer screening : Who and how?. In: Current Urology Reports. 2013 ; Vol. 14, No. 3. pp. 192-198.
@article{c84365fb6d174aac9be2d05df5b95480,
title = "Risk-based prostate cancer screening: Who and how?",
abstract = "The purpose of this review is to identify clinical risk factors for prostate cancer and to assess the utility and limitations of our current tools for prostate cancer screening. Prostate-specific antigen is the single most important factor for identifying men at increased risk of prostate cancer but is best assessed in the context of other clinical factors; increasing age, race, and family history are well-established risk factors for the diagnosis of prostate cancer. In addition to clinical risk calculators, novel tools such as multiparametric imaging, serum or urinary biomarkers, and genetic profiling show promise in improving prostate cancer diagnosis and characterization. Optimal use of existing and future tools will help alleviate the problems of overdiagnosis and overtreatment of low-risk prostate cancer without reversing the substantial mortality declines that have been achieved in the screening era.",
keywords = "Clinical risk, Prostate cancer, Prostate-specific antigen, Risk-based, Screening tools",
author = "Glass, {Allison S.} and Cary, {K. Clinton} and Cooperberg, {Matthew R.}",
year = "2013",
month = "6",
doi = "10.1007/s11934-013-0319-8",
language = "English (US)",
volume = "14",
pages = "192--198",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Risk-based prostate cancer screening

T2 - Who and how?

AU - Glass, Allison S.

AU - Cary, K. Clinton

AU - Cooperberg, Matthew R.

PY - 2013/6

Y1 - 2013/6

N2 - The purpose of this review is to identify clinical risk factors for prostate cancer and to assess the utility and limitations of our current tools for prostate cancer screening. Prostate-specific antigen is the single most important factor for identifying men at increased risk of prostate cancer but is best assessed in the context of other clinical factors; increasing age, race, and family history are well-established risk factors for the diagnosis of prostate cancer. In addition to clinical risk calculators, novel tools such as multiparametric imaging, serum or urinary biomarkers, and genetic profiling show promise in improving prostate cancer diagnosis and characterization. Optimal use of existing and future tools will help alleviate the problems of overdiagnosis and overtreatment of low-risk prostate cancer without reversing the substantial mortality declines that have been achieved in the screening era.

AB - The purpose of this review is to identify clinical risk factors for prostate cancer and to assess the utility and limitations of our current tools for prostate cancer screening. Prostate-specific antigen is the single most important factor for identifying men at increased risk of prostate cancer but is best assessed in the context of other clinical factors; increasing age, race, and family history are well-established risk factors for the diagnosis of prostate cancer. In addition to clinical risk calculators, novel tools such as multiparametric imaging, serum or urinary biomarkers, and genetic profiling show promise in improving prostate cancer diagnosis and characterization. Optimal use of existing and future tools will help alleviate the problems of overdiagnosis and overtreatment of low-risk prostate cancer without reversing the substantial mortality declines that have been achieved in the screening era.

KW - Clinical risk

KW - Prostate cancer

KW - Prostate-specific antigen

KW - Risk-based

KW - Screening tools

UR - http://www.scopus.com/inward/record.url?scp=84878701520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878701520&partnerID=8YFLogxK

U2 - 10.1007/s11934-013-0319-8

DO - 10.1007/s11934-013-0319-8

M3 - Article

VL - 14

SP - 192

EP - 198

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 3

ER -